Accueil › Cancer du sein triple négatif › Massachusetts › Boston
Essais cliniques pour Cancer du sein triple négatif à Boston, MA
26 études pour Cancer du sein triple négatif recherchent des participants dans et autour de Boston (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Recrutement en coursPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 1
- Dana Farber Cancer Institute, Boston
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Recrutement en coursPhase 1
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Recrutement en coursPhase 3
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
Recrutement en cours
- Massachusetts General Hospital, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Recrutement en coursPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Recrutement en coursPhase 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Recrutement en coursPhase 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Recrutement en coursPhase 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Recrutement en coursPhase 1
- Dana-Farber Cancer Institute, Boston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Recrutement en coursPhase 2/3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Recrutement en coursPhase 2
- Dana-Farber Cancer Institute, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Recrutement en coursPhase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Recrutement en coursPhase 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan In TNBC
Recrutement en coursPhase 2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Recrutement en coursPhase 1
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Recrutement en coursPhase 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Recrutement en coursPhase 2
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Recrutement en coursPhase 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Recrutement en coursPhase 1
- Dana Farber Cancer Institute, Boston
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Recrutement en coursPhase 1
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Recrutement en coursPhase 1/2
- Massachusetts General Hospital, Boston
Essais pour Cancer du sein triple négatif dans d'autres villes
- Houston, TX42 études
- New York City, NY31 études
- Nashville, TN28 études
- Los Angeles, CA27 études
- San Antonio, TX23 études
- St. Louis, MO21 études
- Arlington, VA20 études
- Atlanta, GA20 études
- Dallas, TX18 études
- Chicago, IL16 études
- Columbus, OH16 études
- Grand Rapids, MI15 études
Autres études à Boston
- Cancer du sein112 études
- Cancer du poumon non à petites cellules90 études
- Cancer (tous types)85 études
- Cancer métastatique63 études
- Cancer colorectal63 études
- Cancer du poumon62 études
- Cancer de l'ovaire61 études
- Cancer de la prostate59 études
- Dépression52 études
- Cancer de l'endomètre50 études
- Insuffisance cardiaque44 études
- Leucémie aiguë myéloïde44 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.